$CLBT

GEE DAVID NICHOLAS sold $4K of CLBT

GEE DAVID NICHOLAS (Chief Marketing Officer) sold 230 shares of Cellebrite DI Ltd. (CLBT) at $16.07 on 2026-08-12.

Original reporting
SEC EDGAR · GEE DAVID NICHOLAS
Published Aug 13, 2026, 12:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The newest disclosed fact is the CMO’s open-market sale of 230 shares at a stated price, with post-transaction holdings reported.

02

Market read

A small insider sale was disclosed via Form 4; it is unlikely to materially change trading expectations for CLBT.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; the filing does not indicate any change in business outlook.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-13, transaction dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Cellebrite DI Ltd. (CLBT).

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Cellebrite insider Form 4 shows CMO GEE DAVID NICHOLAS sold 230 shares on 2026-08-12 at $16.0678, totaling $3,695.59.

Expected impact

Low near-term impact; any price reaction would be sentiment-driven and likely limited.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction value is modest ($3.7k) and provides no new company-specific operational or financial information.

Market effects

No clear sector read-through from a small, routine insider sale.

None indicated.

None indicated.

Counterpoint

Even small insider sales can be interpreted as reduced confidence, especially since no 10b5-1 plan is stated, but the scale here limits conviction.

Key entities

  • Cellebrite DI Ltd.

    Company subject of the Form 4 insider transaction disclosure.

  • GEE DAVID NICHOLAS

    Chief Marketing Officer who sold 230 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.